Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain

[1] Goodin DS(2002)Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for clinical practice guidelines Neurology 58 169-178

[2] Frohman EM(2002)Epidemiology and current treatment of multiple sclerosis in Europe today J. Rehabil. Res. Dev. 39 175-185

[3] Garmany GP(1995)Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain J. Neurol. Neurosurg. Psychiatry 58 577-581

[4] Pozzilli C(1998)Multiple sclerosis in Mostoles, central Spain Acta Neurol. Scand. 98 238-242

[5] Romano S(1999)Prevalence of multiple sclerosis in Vallaloid, northern Spain J. Neurol. 246 170-174

[6] Cannoni S(2006)The epidemiology of multiple sclerosis in Europe Eur. J. Neurol. 13 700-722

[7] Bufill E(2007)Prevalence of multiple sclerosis in Santiago de Compostela (Galicia, Spain) Mult. Scler. 13 262-264

[8] Blesa R(2006)Costs and quality of life of multiple sclerosis in Spain Eur. J. Health Econ. 7 S65-S74

[9] Galan I(1996)Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann. Neurol. 39 285-294

[10] Benito-Leon J(1995)Copolymer 1 reduces relapse rates and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial Neurology 45 1268-1276

[1] Goodin DS(2002)Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for clinical practice guidelines Neurology 58 169-178

[2] Frohman EM(2002)Epidemiology and current treatment of multiple sclerosis in Europe today J. Rehabil. Res. Dev. 39 175-185

[3] Garmany GP(1995)Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain J. Neurol. Neurosurg. Psychiatry 58 577-581

[4] Pozzilli C(1998)Multiple sclerosis in Mostoles, central Spain Acta Neurol. Scand. 98 238-242

[5] Romano S(1999)Prevalence of multiple sclerosis in Vallaloid, northern Spain J. Neurol. 246 170-174

[6] Cannoni S(2006)The epidemiology of multiple sclerosis in Europe Eur. J. Neurol. 13 700-722

[7] Bufill E(2007)Prevalence of multiple sclerosis in Santiago de Compostela (Galicia, Spain) Mult. Scler. 13 262-264

[8] Blesa R(2006)Costs and quality of life of multiple sclerosis in Spain Eur. J. Health Econ. 7 S65-S74

[9] Galan I(1996)Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann. Neurol. 39 285-294

[10] Benito-Leon J(1995)Copolymer 1 reduces relapse rates and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial Neurology 45 1268-1276